Here are four notes:
1. Exogen has treated over 1 million patients since being FDA PMA approved in 1994.
2. The system uses low-intensity pulsed ultrasound to stimulate the body’s natural healing process.
3. The new clinical research, Bioventus Observational Non-interventional Exogen Studies, will build on previous data to develop additional clinical knowledge of the product.
4. Bioventus Senior Vice President and Chief Science Offer Alessandro Pavesio said, “BONES represents a significant investment in developing epidemiologically grounded rigorous clinical evidence to support use of Exogen in fractures at risk.”
More device articles:
Baxter’s FLOSEAL may yield cost savings for hospital spinal, cardiac surgeries: 4 things to know
Mizuho OSI opens 4th global training center — 5 details
Medacta reaffirms partnership with OREF — 5 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
